What would you like to look for?
Site search
26 October 2022

Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp (NASDAQ: EBAC), a special purpose acquisition company (SPAC), announced they have entered into a definitive busi-ness combination agreement. Upon closing of the transaction, the company will be named “Oculis Holding SA” and will work to accelerate the development of Oculis’s differentiated ophthalmology pipeline. The transaction includes commitments to an upsized PIPE and private investment of close to USD 80 million, anchored by LSP 7, with the participation of leading institutional investors, including Earlybird, Novartis Venture Fund, Pivotal bioVenture Partners, funds managed by Tekla Capital Management LLC, and VI Partners, among others.

VISCHER AG has been advising Oculis since inception and is also in this business combination and the resulting listing on NASDAQ on all Swiss law aspects. The team is led by Matthias Staehelin with Christian Wyss, Vincent Reardon, Balthasar Müller (all Corporate/M&A), Marc Prinz (Employment) as well as Nadia Tarolli and Adrian Briner (both Tax).